DDInter839 DDInter1376
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Goserelin {u} (Compound) resembles {v} (Compound) Pentagastrin
Goserelin {u} (Compound) resembles {v} (Compound) Cetrorelix
Goserelin {u} (Compound) treats {v} (Disease) breast cancer
Goserelin {u} (Compound) binds {v} (Gene) LHCGR
Goserelin {u} (Compound) upregulates {v} (Gene) SPAG4
Goserelin {u} (Compound) is included by {v} (Pharmacologic Class) Gonadotropin Releasing Hormone Receptor Agonists
Goserelin {u} (Compound) causes {v} (Side Effect) Reaction aggravation
Goserelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Goserelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Goserelin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Goserelin (Compound) resembles Pentagastrin (Compound)
Goserelin (Compound) resembles Cetrorelix (Compound)
Goserelin (Compound) treats breast cancer (Disease)
Goserelin (Compound) binds LHCGR (Gene)
Goserelin (Compound) upregulates SPAG4 (Gene)
Goserelin (Compound) is included by Gonadotropin Releasing Hormone Receptor Agonists (Pharmacologic Class)
Goserelin (Compound) causes Reaction aggravation (Side Effect)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Goserelin may lead to a major life threatening interaction when taken with Dolasetron